Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0000950170-25-025031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | CGEM | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +37.5K | 241.0K | +18% | $0 |
| D | 2025-02-21 | 2025-02-19 | CGEM | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-19 | A | A | 37,500 | $0.00 | 240,990 | D | — | — | (F1) The shares underlying the restricted stock unit vest on an annual basis over four years. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-19 | A | A | 75,000 | $0.00 | 75,000 | D | $9.43 · — to 2035-02-19 | 75,000 Common Stock | (F2) The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |